Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 28, 2016
Pharmacy Choice - News - Over-the-Counter Drugs - May 28, 2016

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 25     Go To Page:

5/27/16 - BioSyent Releases Q1 2016 Results
BioSyent Inc. released today a summary of its financial results for the three months ending March 31, 2016. First quarter 2016 Net Revenues of $3,772,463 increased by 14% versus Q1 2015 Q1 2016 Pharmaceutical Net Revenues of $3,546,608 increased by 10% overall versus Q1 2015, with Canadian Pharmaceutical Net Revenues increasing by 6% and Intern
5/27/16 - Small Healthcare Companies Sometimes Forgotten
The United States is by far the largest consumer of the healthcare market in the world. Advanced Medical Isotope Corp., Nutranomics Inc., KollagenX Corp., Bioelectronics Corp. Medical devices can range across a broad spectrum of innovation. Advanced Medical Isotope Corp. for example, is a medical device company focused on late stage radiation oncol
5/26/16 - FDA Consumer Health Information: Allergy Relief For Your Child
SILVER SPRING, Md., May 26, 2016/ PRNewswire-USNewswire/ View this consumer update on FDA's website: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm273617. htm. Up to 40 percent of children suffer from allergic rhinitis, according to the National Institute of Allergy and Infectious Diseases. The U.S. Food and Drug Administration regulates bot
5/26/16 - Fitch Rates Walgreens Boots Alliance, Inc. $6 Billion Senior Unsecured Notes 'BBB'
Fitch rates WBA's Long-Term Issuer Default Rating' BBB'/Stable Outlook. Of the total $17 billion purchase price for Rite Aid, WBA is funding the acquisition with $14.6 billion of debt, including the assumption of $2.3 billion of Rite Aid's existing unsecured debt. WBA has already obtained $5 billion of term loans in December 2015 and after the issu
5/26/16 - Generic Pharmaceutical Vendor/Wholesaler [TendersInfo (India)]
Tenders are invited for Generic Pharmaceutical Vendor/Wholesaler SCOPE OF CONTRACT: This contract will be used as needed to purchase pharmaceuticals/over-the-counter and medically necessary items from responsive, responsible manufacturers/vendors/wholesalers. Any questions should be submitted in writing to designated contacts by close of...
5/26/16 - Global Animal Medication Industry
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. The report profiles 113 companies including many key and niche players such as- Bayer HealthCare AG Boehringer Ingelheim GmbH Ceva Sant Animale S.A Dechra Pharmaceuticals PLC Eli Lilly and Company Read the full r
5/26/16 - HEALTH & SUPPORT
On Thursday, May 26, from 10 to 11:30 a.m., Stephen T. DiGregorio, Esq, of the Massachusetts Bar Association, will discuss Protecting Your Assets.. The American Cancer Society s Look Good Feel Better program, a free service that teaches cancer patients hands-on cosmetic techniques to help them cope with appearance-related side effects from
5/26/16 - Italy Healthcare, Regulatory and Reimbursement Landscape Report 2016 - Industry Value Will Drop to $18.6 Billion by 2020 due to Struggling Economy
Dublin- Research and Markets has announced the addition of the "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape- Italy" report to their offering. Italy's Pharmaceutical Industry Value Will Drop to $18.6 Billion by 2020 due to Struggling Economy. The pharmaceutical industry in Italy is set to decline from $21.3 billion in 2016 to $1
5/26/16 - Italy Healthcare, Regulatory and Reimbursement Landscape Report 2016 - Industry Value Will Drop to $18.6 Billion by 2020 due to Struggling Economy - Research and Markets
Research and Markets has announced the addition of the "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape- Italy" report to their offering. Italy's Pharmaceutical Industry Value Will Drop to $18.6 Billion by 2020 due to Struggling Economy. The pharmaceutical industry in Italy is set to decline from $21.3 billion in 2016 to $18.6 bill
5/25/16 - Innovus Pharma Signs Exclusive License and Distribution Agreement with BroadMed for EjectDelay in Lebanon
Innovus Eligible to Receive up to $6.2 Million in Upfront and Sales Milestone Payments plus Transfer PriceSan Diego, CA 05/25/2016 Innovus Pharmaceuticals, Inc., an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's healt
5/25/16 - New Phase 3 Study Findings Show STELARA Maintained Clinical Remission After One Year Of Treatment In Patients With Moderate To Severe Crohn's Disease
The Phase 3 IM-UNITI maintenance study, which evaluated 388 patients who achieved clinical response eight weeks after a single intravenous infusion of STELARA in the UNITI -1 and UNITI -2 Phase 3 induction studies, showed that 53 percent of patients receiving a STELARA 90 mg SC injection every eight weeks and 49 percent of patients receiving a STEL
5/25/16 - Silvanols invests EUR 20,000 in development of herbal weight loss product line
RIGA, May 25- Latvian pharmaceutical company Silvanols has invested EUR 20,000 in development of a herbal weight loss product line, Easyslim, the company announced. Last year Silvanols generated EUR 4.11 million in turnover compared to EUR 3.24 million in 2014 and earned a profit of EUR 230,342 as opposed to a loss of EUR 86,130 in 2014.. Silvanols
5/25/16 - U.S. FDA Expands Indication of INVOKAMET (canagliflozin/metformin HCl) to Include First-Line Treatment of Adults with Type 2 Diabetes
Release date- 24052016- RARITAN, N.J- Janssen Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration has approved INVOKAMET, a fixed-dose combination therapy of INVOKANA and metformin hydrochloride, for first-line treatment of adults with type 2 diabetes. INVOKAMET, the first combination of a sodium glucose co-transporter 2 in
5/24/16 - Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%
Allergan plc today announced that the New Drug Application filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema associated with rosacea in adults, has been accepted by the U.S. Allergan expects the Prescription Drug User Fee Act date to be in the first half of 201
5/24/16 - IDegLira receives unanimous 16-0 vote in favor of approval from FDA Advisory Committee
Based on the data contained in the New Drug Application for IDegLira, the FDA asked the panel members to discuss whether Novo Nordisk has provided adequate evidence to establish the efficacy and safety profile of IDegLira for the treatment of adults with type 2 diabetes. The NDA for IDegLira was submitted to the FDA in September 2015 under the FDA'
5/24/16 - U.S. FDA Expands Indication of INVOKAMET (canagliflozin/metformin HCl) to Include First-Line Treatment of Adults with Type 2 Diabetes
Janssen Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration has approved INVOKAMET , a fixed-dose combination therapy of INVOKANA and metformin hydrochloride, for first-line treatment of adults with type 2 diabetes. INVOKAMET , the first combination of a sodium glucose co transporter 2 inhibitor and metformin av
5/23/16 - BUYINS.NET: BUYINS.NET: AET, IGN, LPNT, CVO, CNC, DXCM Are Seasonally Ripe To Go Up In the Next Five Weeks
May 23, 2016/ M2 PRESSWIRE/ BUYINS.NET/ www.squeezetrigger.com is monitoring the Seasonality of Aetna Inc, iShares S&P North Amer Tech-Multimedia Net Idx Fd, LifePoint Hospitals Inc, Cenveo Inc, CENTENE CORPORATION, DexCom Inc and each have a high seasonal probability to go Up in the next weeks. AET Aetna Inc 4.42% 76.47% Friday, June 3rd 2016.
5/23/16 - Heartburn drug damages blood vessel cells in lab finding
By a News Reporter-Staff News Editor at Clinical Trials Week DALLAS, A popular over-the-counter medication for heartburn, caused laboratory blood vessel cells to age quicker, according to new research in Circulation Research, an American Heart Association journal. In fact, the U.S. Food and Drug Administration estimates that 1 in 14 Americans hav
5/23/16 - How would Bayer-Monsanto affect workers, farmers, investors?
Bayer wants to buy Monsanto for $62 billion, hooking up the German chemical and drug company with the St. Louis- based producer of seeds and weed-killers. A: Bayer is offering to acquire Monsanto, which makes seeds for fruits, vegetables, corn, soybeans and cotton, as well as weed-killer Roundup. That compares with a closing price Friday of $101
5/23/16 - Orexigen Appoints New Member of Board of Directors and Announces Senior Management Changes
Orexigen Therapeutics, Inc. today announced the appointment of Deborah A. Jorn to its Board of Directors, effective immediately. Prior to Valeant, she was the Chief Global Marketing Officer at Bausch and Lomb Pharmaceuticals and served as the commercial head of their $1.3 billion Global Pharmaceutical Division which included both Rx and OTC brand
5/23/16 - Purdue Pharma Announces Patent Agreement with Egalet and Acura
Purdue Pharma L.P. today announced that the Company has entered into an agreement with Egalet Corporation and Acura Pharmaceuticals, Inc. that will settle various patent claims. "This agreement reflects the commitment of Purdue Pharma to seek solutions that will enhance collaboration in the fight against prescription drug abuse," said Philip C..
5/23/16 - SeeThruEquity Issues Update Note on Innovus Pharmaceuticals, Inc. (OTCQB: INNV) with a Price Target of $0.91
NEW YORK, NY/ ACCESSWIRE/ May 23, 2016/ SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on Innovus Pharmaceuticals, Inc.. Innovus Pharmaceuticals, Inc. is an emerging commercial stage pharmaceutical
5/23/16 - SKINVISIBLE INC - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995,
5/23/16 - Staff Standpoint: So?What Is the FDA to Do?
HR Editor Karl Strom considers what the FDA can do in the wake of its recent GMP workshop, the PCAST recommendations, and impending report from the IOM. Would these proposals lead to more innovation, affordability and accessibility for consumers...or represent a giant step backward?
5/22/16 - Stakeholders commit to combat fake contraceptives
At a joint meeting of officials of the Federal Ministry of Health, the National Agency for Food and Drug Administration and Control, Pharmaceutical Council of Nigeria, and Society for Family Health which held in Abuja, it was highlighted that the emergency contraceptive market represents one of the segments of the Nigeria medicines and consumables
Articles(s): 1 - 25 of 25     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415